Is Imugene Limited (IUGNF) a Buy, Sell, or Hold?
OTC : IUGNF
Imugene Limited
$0.07 USD
$0.01 (7.69%)
- Volume
- 50K
- Average Volume
- 24.74K
- Market Capitalization
- $29.12M
- P/E Ratio
- -0.37
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.31
- Year Low
- $0.06
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.78
Company Overview
OTC
Leslie Chong
Biotechnology
Healthcare
IUGNF
5
AU
USD
Liquidity Metrics
0.12
1.78
1.68
0.77
0.00
Sales & Valuation
$4.4M
12.80
0.57
-0.67
-0.20
Profitability
-$0.32
-$69.02M
-1864.12%
-1841.69%
-134.65%
-86.46%
P/E Metrics
-0.37
0.00
0.00
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
-15.93
1/9
$14.15M
$67.64M
$25.79M
-$187.78M
Key Metrics (TTM)
$31.53M
10.05
-0.53
1.78
-134.65%
-108.88%
-241.54%
-146.89%
-77 days
Company Executives
| Name | Title |
|---|---|
| Leslie Chong | CEO & MD |
| John Byon | Chief Medical Officer |
| Paul Edward-Alexander Hopper FAICD | Executive Chairman |
| Ursula McCurry | Chief Clinical Operations Officer |
| Darren Michael Keamy | Chief Financial Officer & Company Secretary |
Poll Results
No votes yet today — be the first to share your view!
About Imugene Limited (OTC:IUGNF) Stock
Imugene Limited, an Australian firm specializing in clinical-stage immuno-oncology, is dedicated to conceiving diverse immunotherapies. Its core mission involves activating the immune systems of cancer patients to effectively combat and eradicate malignant growths. The company's primary therapeutic candidate is HER-Vaxx, a vaccine engineered for HER2-positive cancers. This treatment operates by stimulating a broad polyclonal antibody response against HER2/neu receptors, specifically addressing gastric and breast cancers. Currently, HER-Vaxx is undergoing Phase 1b/2 clinical evaluation for its application in gastric cancer. Beyond its lead product, Imugene is also advancing PD1-Vaxx, another cancer vaccine designed to induce the body to generate polyclonal antibodies that block PD-1 signali ... ng. Additionally, they are developing CF33, a potent oncolytic virus constructed from a unique combination of genomic sequences sourced from various vaccinia virus strains. Imugene has forged a research collaboration with Celularity Inc. to integrate its CD19 oncolytic virus technology with Celularity's CD19-targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19, for the treatment of solid tumors. Furthermore, the company maintains a strategic partnership with Eureka Therapeutics, Inc. Established in 1986, Imugene Limited is headquartered in Sydney, Australia.
Figma shares rise as Bank of America resumes coverage with a ‘Buy’ rating
2026-07-07 12:02:00
Figma (NYSE:FIG) was reinstated with a ‘Buy’ rating and a $30 price objective by Bank of America, with the firm arguing that artificial intelligence is...
Imugene raises $11.1 million to advance azer-cel after complete responses in early cohort
2026-07-07 07:36:00
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) is raising about A$11.12 million before costs through a two-tranche placement, strengthening its balance sheet as...
Shell flags 'significantly higher' gas trading and sells South Africa business - UPDATE
2026-07-07 04:38:00
Shell PLC (LSE:SHEL, NYSE:SHEL) shares jumped over 2% after it said stronger trading and improved refining margins should support second-quarter...
Imugene reports second BTKi cohort response - ICYMI
2026-07-04 06:00:00
Imugene Ltd (ASX:IMU, OTC:IUGNF) earlier this week reported a second complete response in the concurrent Bruton Tyrosine Kinase inhibitor, or BTKi, cohort...
Imugene CEO details azer-cel trial milestone - ICYMI
2026-07-03 06:41:00
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) earlier this week reported the first complete response in the concurrent Bruton Tyrosine Kinase inhibitor, or...
Anthropic clears export hurdle for Fable 5, easing a threat to its IPO story
2026-07-01 07:10:00
The most striking thing about the standoff that ended on Tuesday is not that it ended, but that it happened at all: a US government blocking a US company...
Imugene reports second complete response in azer-cel BTKi cohort
2026-07-01 06:59:00
Just a day after reporting the first complete response in the concurrent Bruton Tyrosine Kinase inhibitor (BTKi) cohort of its ongoing Phase 1b azer-cel...
Fed may adopt leaner communications strategy under Warsh, says Deutsche Bank
2026-07-01 06:00:00
Federal Reserve communications are likely to become shorter, less reliant on forward guidance and more focused on longer-term economic narratives under new...
Frequently Asked Questions
-
What is the current Imugene Limited (IUGNF) stock price?
-
Imugene Limited(OTC:IUGNF) stock price is $0.07 in the last trading session. During the trading session, IUGNF stock reached the peak price of $0.3101 while $0.055 was the lowest point it dropped to. The percentage change in IUGNF stock occurred in the recent session was 7.69% while the dollar amount for the price change in IUGNF stock was $0.01.
-
IUGNF's industry and sector of operation?
-
The OTC listed IUGNF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of IUGNF?
-
Leslie Chong | CEO & MD
John Byon | Chief Medical Officer
Paul Edward-Alexander Hopper FAICD | Executive Chairman
Ursula McCurry | Chief Clinical Operations Officer
Darren Michael Keamy | Chief Financial Officer & Company Secretary -
How many employees does IUGNF have?
-
Number of IUGNF employees currently stands at 5. IUGNF operates from 4-6 Bligh Street, Sydney, NSW 2000, AU.
-
Link for IUGNF official website?
-
Official Website of IUGNF is: https://www.imugene.com
-
How do I contact IUGNF?
-
IUGNF could be contacted at phone #61 2 9423 0881 and can also be accessed through its website. IUGNF operates from 4-6 Bligh Street, Sydney, NSW 2000, AU.
-
How many shares of IUGNF are traded daily?
-
The average number of IUGNF shares traded daily for last 3 months was 24.74K.
-
What is the market cap of IUGNF currently?
-
The market value of IUGNF currently stands at $29.12M with its latest stock price at $0.07